Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$67.45 USD

67.45
20,837,305

-8.33 (-10.99%)

Updated Sep 19, 2025 03:59 PM ET

After-Market: $67.63 +0.18 (0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Benjamin Rains headshot

2 Strong Stocks Trading 30% Below Their Highs to Buy in December

by Benjamin Rains

Why investors might want to buy Global Payments (GPN) and DexCom (DXCM) stock right now for long-term growth, with both trading at least 30% below their record highs.

Zacks Equity Research

Thermo Fisher (TMO) Extends Partnership With Flagship Pioneering

by Zacks Equity Research

Thermo Fisher's (TMO) in-depth knowledge of the life sciences sector will be combined with Flagship Pioneering to create revolutionary capabilities for the ecosystem.

Zacks Equity Research

Here's Why Investors Should Hold Humana (HUM) Stock for Now

by Zacks Equity Research

Humana (HUM) is expected to benefit from a strong growth outlook, upgraded health plan offering suite, expanding Medicare Advantage membership, and solid cash reserves.

Zacks Equity Research

Charles River (CRL) Gains on Price & Volume Growth Amid FX Woe

by Zacks Equity Research

At present, Charles River (CRL) is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.

Zacks Equity Research

Inspira (IINN) Expands in Life Support Space With New Deal

by Zacks Equity Research

According to Inspira (IINN), the integration of its technology to oxygenate blood combined with Ennocure's infection prevention solutions is likely to help improve patient outcomes in ICUs.

Zacks Equity Research

Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE Trial

by Zacks Equity Research

Penumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT.

Zacks Equity Research

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business.

Zacks Equity Research

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH), driven by a recovery in business and an expanding global footprint.

Zacks Equity Research

Quest Diagnostics' (DGX) New Pact to Scale Precision Medicine

by Zacks Equity Research

Quest Diagnostics' (DGX) will supply next-generation sequencing and enhanced RNA extraction services for Scipher's PrismRA test through a new collaboration.

Zacks Equity Research

Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics

by Zacks Equity Research

Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.

Zacks Equity Research

Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal

by Zacks Equity Research

Charles River (CRL) and GC4K announce a gene therapy manufacturing collaboration.

Zacks Equity Research

Should Vanguard Mid-Cap Growth ETF (VOT) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VOT

Zacks Equity Research

Here's Why Investors Should Retain Molina Healthcare (MOH) Now

by Zacks Equity Research

Molina Healthcare (MOH) is well-poised for improvement on the back of membership growth in the Medicaid and Medicare businesses. Acquisitions and a solid cash balance act as added tailwinds.

Zacks Equity Research

Smith & Nephew (SNN) New Buyout Expands Sports Medicine Suite

by Zacks Equity Research

Smith & Nephew (SNN) will pay an initial cash consideration of $180 million at closure, with an additional $150 million based on financial performance to acquire CartiHeal.

Zacks Equity Research

Penumbra's (PEN) Expansion Moves, New Launches Aid Growth

by Zacks Equity Research

Penumbra (PEN) expects to materially increase both revenues and profitability of the international business in the next three years and beyond.

Zacks Equity Research

Why DexCom (DXCM) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and DexCom (DXCM) have performed compared to their sector so far this year.

Zacks Equity Research

Philips (PHG) Bolsters Diagnostic Imaging With New Launches

by Zacks Equity Research

Philips (PHG) unveils an array of AI-enabled innovations at RSNA23 to enhance diagnostic imaging capabilities across healthcare providers.

Zacks Equity Research

Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System

by Zacks Equity Research

Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.

Zacks Equity Research

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors remain optimistic about Teleflex (TFX) on the strength of the Vascular and Interventional businesses.

Zacks Equity Research

Philips (PHG) Adds BlueSeal to its Diagnostic Imaging Portfolio

by Zacks Equity Research

Philips (PHG) showcases BlueSeal MR Mobile to enhance diagnostic imaging capabilities across remote and rural communities.

Zacks Equity Research

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors are increasingly optimistic about Labcorp (LH) due to development in targeted high-growth areas.

Zacks Equity Research

Orthofix (OFIX) Q3 Earnings Top Estimates, 2023 Sales View Cut

by Zacks Equity Research

Orthofix (OFIX) saw very strong growth across multiple business segments and product lines in Q3.

Zacks Equity Research

Labcorp (LH) Closes the Legacy Health Asset Acquisition Deal

by Zacks Equity Research

Labcorp (LH) finalizes the comprehensive laboratory relationship with Legacy Health.

Zacks Equity Research

Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.